Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or CLDN6, x CD3 T cell engaging bispecific antibody. The Phase 1 dose escalation and expansion trial is enrolling patients with CLDN6-positive gynecologic and testicular cancers. The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The study is expected to enroll up to 70 patients.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Context Therapeutics Appoints Andy Pasternak as Chairman
- Context Therapeutics appoints PAsternak as Chairman of board of directors
- Context Therapeutics initiated with an Outperform at JMP Securities
- Context Therapeutics Secures Funding for Cancer Therapy Pipeline
- Context Therapeutics initiated with a Buy at D. Boral Capital